Edward Loftus, MD
Gastroenterology · Rochester, MNNPI 1003895590
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $220,442 of the $281,717 with a category attached, or 78.2%. It is spread thinly across 24 manufacturers, the largest accounting for just 17.7%. Among gastroenterology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $1241.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$50K
- AbbVie$49K
- Eli Lilly$36K
- Johnson & Johnson$31K
- Genentech, Inc.$22K
- Janssen Global Services, LLC$18K
- plus $77K from 18 others
Across 1,086 payments — averaging $4571.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3.7M
- Bristol Myers Squibb$257K
- Roche Products Limited$215K
- Janssen Research & Development, LLC$203K
- Gilead$203K
- Takeda Pharmaceuticals U.S.A., Inc.$144K
- plus $256K from 6 others
What the payments were for
- Consulting fees$220,44278%
- Speaking & faculty fees$22,9328%
- Travel & lodging$35,37413%
- Food & beverage$2,8831%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $49,925 |
| AbbVie(2 entities) | 49 | $48,709 |
| Eli Lilly | 21 | $35,500 |
| Johnson & Johnson | 37 | $31,028 |
| Genentech, Inc. | 12 | $21,955 |
| Janssen Global Services, LLC | 12 | $17,664 |
| Gilead | 13 | $15,475 |
| Pfizer | 11 | $11,955 |
| E.r. Squibb & Sons, L.L.C. | 6 | $10,753 |
| Janssen Scientific Affairs, LLC | 9 | $6,276 |
| Merck | 6 | $6,078 |
| Lilly USA, LLC | 2 | $5,850 |
| Bristol Myers Squibb | 6 | $3,738 |
| Janssen Research & Development, LLC | 4 | $3,100 |
| Celltrion USA Inc. | 3 | $2,865 |
| Boehringer Ingelheim | 1 | $2,600 |
| UCB, Inc. | 2 | $2,600 |
| Celltrion Healthcare Co., Ltd | 2 | $2,000 |
| Boehringer Ingelheim International GmbH | 1 | $1,600 |
| Amgen | 2 | $1,250 |
| Fresenius Kabi USA, LLC | 1 | $610 |
| Steris Corporation | 1 | $101 |
| AstraZeneca | 1 | $68 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$281,717 in reported general payments places this provider in the 95th percentile of 365 gastroenterology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 111 | $3,426,353 |
| Skyrizi On-BodyRisankizumab-Rzaa | 20 | $429,937 |
| Humira(Cf) PenAdalimumab | 46 | $398,443 |
| Humira PenAdalimumab | 18 | $238,763 |
| Cimzia (2 Pack)Certolizumab Pegol | 35 | $193,520 |
| RinvoqUpadacitinib | 22 | $145,225 |
| XifaxanRifaximin | 30 | $91,846 |
| Mesalamine | 30 | $14,343 |
| Budesonide DrBudesonide | 33 | $13,124 |
| Vancomycin Hcl | 15 | $10,086 |
| Ondansetron OdtOndansetron | 16 | $4,100 |
| Budesonide EcBudesonide | 11 | $3,161 |
| Balsalazide Disodium | 20 | $2,251 |
| Azathioprine | 35 | $2,241 |
| LoperamideLoperamide Hcl | 27 | $2,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $31,028 | $3,426,353111 claims |
| UCB, Inc.Cimzia (2 Pack) | $2,600 | $193,52035 claims |
| AbbVieRinvoq | $48,709 | $145,22522 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $610 | $3513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 365 gastroenterology providers in Minnesota.
Other gastroenterology in Rochester
- John KisielRochester$856K
- Christopher GostoutRochester$299K
- Alina AllenRochester$277K
- Todd BaronRochester$270K
- Sahil KhannaRochester$242K
- Joseph MurrayRochester$234K
- Andres AcostaRochester$224K
- David LarsonRochester$142K
- Ibrahim HanounehRochester$104K
- Bret PetersenRochester$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.